$0.95
3.03% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US68404V1008
Symbol
OPTN

OptiNose, Inc. Stock price

$0.95
-0.05 4.83% 1M
-0.80 45.62% 6M
-0.34 26.22% YTD
-0.28 22.63% 1Y
-1.91 66.72% 3Y
-6.04 86.38% 5Y
-18.05 94.99% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.03 3.03%
ISIN
US68404V1008
Symbol
OPTN
Sector

Key metrics

Market capitalization $143.49m
Enterprise Value $178.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.38
P/S ratio (TTM) P/S ratio 1.91
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 3.91%
Revenue (TTM) Revenue $75.06m
EBIT (operating result TTM) EBIT $-18.83m
Free Cash Flow (TTM) Free Cash Flow $-35.54m
Cash position $91.36m
EPS (TTM) EPS $-0.37
P/E forward negative
P/S forward 1.66
EV/Sales forward 2.06
Short interest 5.86%
Show more

Is OptiNose, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

OptiNose, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a OptiNose, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a OptiNose, Inc. forecast:

Buy
100%

Financial data from OptiNose, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
75 75
4% 4%
100%
- Direct Costs 7.96 7.96
15% 15%
11%
67 67
7% 7%
89%
- Selling and Administrative Expenses 81 81
11% 11%
108%
- Research and Development Expense 4.70 4.70
47% 47%
6%
-18 -18
50% 50%
-25%
- Depreciation and Amortization 0.39 0.39
13% 13%
1%
EBIT (Operating Income) EBIT -19 -19
50% 50%
-25%
Net Profit -41 -41
12% 12%
-55%

In millions USD.

Don't miss a Thing! We will send you all news about OptiNose, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

OptiNose, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in th...
Neutral
GlobeNewsWire
12 days ago
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET.
Neutral
Seeking Alpha
28 days ago
OptiNose, Inc. (NASDAQ:OPTN ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Paul Spence - Chief Commercial Officer Conference Call Participants Schuyler van den Broek - Piper Sandler Thomas Flaten - Lake Street Capital Markets Operator Hello, and welcome to the OptiNose Second Quarter 2024 Ear...
More OptiNose, Inc. News

Company Profile

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Head office United States
CEO Ramy Mahmoud
Employees 132
Founded 2000
Website www.optinose.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today